Inicio>>Signaling Pathways>> Tyrosine Kinase>> FGFR>>TAS-120

TAS-120 (Synonyms: TAS-120)

Catalog No.GC19156

TAS-120 (TAS-120) es un inhibidor de FGFR biodisponible por vÍa oral, altamente selectivo e irreversible, con IC50 de 3,9, 1,3, 1,6 y 8,3 nM para FGFR 1-4, respectivamente. TAS-120 inhibe el FGFR2 mutante y de tipo salvaje con IC50 similares (FGFR2 de tipo salvaje = 0,9 nM; V5651 = 1-3 nM; N550H = 3,6 nM; E566G = 2,4 nM).

Products are for research use only. Not for human use. We do not sell to patients.

TAS-120 Chemical Structure

Cas No.: 1448169-71-8

Tamaño Precio Disponibilidad Cantidad
1mg
54,00 $
Disponible
5mg
135,00 $
Disponible
10mg
198,00 $
Disponible
25mg
378,00 $
Disponible
50mg
585,00 $
Disponible

Tel:(909) 407-4943 Email: sales@glpbio.com

Reseñas de cliente

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Protocol Chemical Properties Product Documents Related Products

Futibatinib (TAS-120) is an orally bioavailable, highly selective, and irreversible FGFR inhibitor. Futibatinib (TAS-120) covalently binds to a highly conserved P-loop cysteine residue in the ATP pocket of FGFR. Futibatinib (TAS-120) exhibits potency at low nanomolar concentrations and high specificity against wild-type FGFR1/2/3/4 as well as against some FGFR2 kinase domain mutations[1][2].

Futibatinib (TAS-120) (3, 30, 100 mg/kg/day, p.o.) exerts an anti-tumor effect in mice. Futibatinib (TAS-120) shows anti-tumor effect by administering at moderate intervals, such as intermittent administration of every other day dosing and 2 times/week, and reducing the sustained elevation and weight suppression blood phosphorus level, and take a antitumor effective as daily administration[1].

References:
[1]. Goyal L, et al. TAS-120 Overcomes Resistance to ATP-Competitive FGFR Inhibitors in Patients with FGFR2 Fusion-Positive Intrahepatic Cholangiocarcinoma. Cancer Discov. 2019 Aug;9(8):1064-1079.
[2]. Kalyukina M, et al. TAS-120 Cancer Target Binding: Defining Reactivity and Revealing the First Fibroblast Growth Factor Receptor 1 (FGFR1) Irreversible Structure. ChemMedChem. 2019 Feb 19;14(4):494-500.

Reseñas

Review for TAS-120

Average Rating: 5 ★★★★★ (Based on Reviews and 27 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for TAS-120

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.